title: Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone.
abstract: The effect of a single intravenous (i.v.) infusion of 5 mg alendronate was studied in ten patients with Paget's disease, six patients with primary hyperparathyroidism and ten osteopenic postmenopausal women. Urinary hydroxyproline excretion significantly decreased within few days in all patients (from 113 +/- 67.9 to 58 +/- 35 mmol/mol Cr in Paget's disease, from 21.8 +/- 9 to 12.9 +/- 6 mmol/mol Cr in hyperparathyroidism, from 18.7 +/- 9.5 to 8.5 +/- 4.3 mmol/mol Cr in postmenopausal women). In the patients with Paget's disease urinary hydroxyproline remained suppressed over the 6 months of follow-up, whereas it rose toward pretreatment values within 4 and 6 weeks in the patients with primary hyperparathyroidism and in postmenopausal osteopenic women, respectively. Plasma alkaline phosphatase significantly fell only after 4-6 weeks in patients with primary hyperparathyroidism and in Pagetic patients. In the latter group alkaline phosphatase continued to decline thereafter and a plateau became apparent after 2 months. In postmenopausal women the serum alkaline phosphatase remained unchanged. Thus, the same dose of alendronate induces comparable fractional decreases of bone resorption in the three groups of patients, but the effect is persistent only in Paget's disease. This is consistent with the hypothesis that alendronate inhibits osteoclastic activity only at the level of the existing resorption sites. In osteoporotic and primary hyperparathyroid patients, as soon as the treatment is withdrawn, the appearance of new sites of resorption is not inhibited and bone turnover is resumed to pre-treatment values.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Istituto di Semeiotica e Nefrologia Medica, University of Verona, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Adami
authors.forename: N
authors.initials: N
authors.lastname: Zamberlan
authors.forename: M
authors.initials: M
authors.lastname: Mian
authors.forename: R
authors.initials: R
authors.lastname: Dorizzi
authors.forename: M
authors.initials: M
authors.lastname: Rossini
authors.forename: B
authors.initials: B
authors.lastname: Braga
authors.forename: D
authors.initials: D
authors.lastname: Gatti
authors.forename: F
authors.initials: F
authors.lastname: Bertoldo
authors.forename: V
authors.initials: V
authors.lastname: Locascio
mesh_terms: D000368:Aged; D019386:Alendronate; D000469:Alkaline Phosphatase / Q000097:blood; D001851:Bone Diseases, Metabolic / Q000188:drug therapy*; D001862:Bone Resorption / Q000188:drug therapy; D002118:Calcium / Q000097:blood; D004164:Diphosphonates / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D006961:Hyperparathyroidism / Q000188:drug therapy*; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010001:Osteitis Deformans / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000097:blood; D010710:Phosphates / Q000097:blood; D017698:Postmenopause
chemical_list: D004164:Diphosphonates; D010281:Parathyroid Hormone; D010710:Phosphates; D000469:Alkaline Phosphatase; D006909:Hydroxyproline; D002118:Calcium; D019386:Alendronate